Ramucirumab for advanced gastric cancer or gastro-oesophageal junction adenocarcinoma

被引：22

作者：

Young, Kate ^{[1
]}

Smyth, Elizabeth ^{[1
]}

Chau, Ian ^{[1
]}

机构：

[1] Royal Marsden Hosp, Gastrointestinal Oncol Unit, Sutton SM2 5PT, Surrey, England

来源：

THERAPEUTIC ADVANCES IN GASTROENTEROLOGY | 2015年 / 8卷 / 06期

关键词：

angiogenesis; gastric cancer; gastro-oesophageal cancer; ramucirumab; vascular endothelial growth factor; vascular endothelial growth factor receptor 2; RANDOMIZED PHASE-III; 2ND-LINE CHEMOTHERAPY; 1ST-LINE THERAPY; SUPPORTIVE CARE; DOUBLE-BLIND; OPEN-LABEL; GROWTH; COMBINATION; PLUS; VEGF;

D O I：

10.1177/1756283X15592586

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Ramucirumab, a fully humanized monoclonal antibody directed against vascular endothelial growth factor receptor 2, is the first targeted agent to have demonstrated an improvement in survival, as a single agent or in combination, in a molecularly unselected population in gastro-oesophageal cancer. Now that second-line treatment is routinely considered for patients with advanced gastro-oesophageal cancer, ramucirumab, with its favourable toxicity profile compared with cytotoxic treatment, provides a valuable additional treatment option.

引用

页码：373 / 383

页数：11

共 50 条

[1] Ramucirumab use in patients with advanced gastric cancer (AGC) or gastro-oesophageal junction (GEJ) adenocarcinoma in Spain: RAMIS observational study
Longo Munoz, F.
Jorge Fernandez, M.
Tur, R. Yaya
Diaz, S.
Ortega, M.
Dilla, T.
Molero, A.
Cervera, J. M.
[J]. ANNALS OF ONCOLOGY, 2019, 30
[2] Ramucirumab plus paclitaxel as a second-line treatment for advanced gastric or gastro-oesophageal junction cancer
[J]. Nature Reviews Gastroenterology & Hepatology, 2014, 11 (11) : 642 - 642
[3] ECONOMIC EVALUATION OF RAMUCIRUMAB AS SECOND-LINE CHEMOTHERAPY FOR PREVIOUSLY TREATED ADVANCED GASTRIC OR GASTRO-OESOPHAGEAL JUNCTION ADENOCARCINOMA IN CHINA
Luo, X.
Peng, L.
Tan, C.
Wan, X.
Zeng, X.
[J]. VALUE IN HEALTH, 2018, 21 : S33 - S33
[4] Trastuzumab Deruxtecan: A Review in Gastric or Gastro-Oesophageal Junction Adenocarcinoma
Connie Kang
[J]. Targeted Oncology, 2023, 18 (6) : 981 - 989
[5] Trastuzumab Deruxtecan: A Review in Gastric or Gastro-Oesophageal Junction Adenocarcinoma
Kang, Connie
[J]. TARGETED ONCOLOGY, 2023, 18 (06) : 981 - 989
[6] The ATTRACTION of nivolumab for gastric and gastro-oesophageal junction cancer
Katrina Ray
[J]. Nature Reviews Gastroenterology & Hepatology, 2017, 14 (12) : 690 - 690
[7] Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Buyukkaramikli, Nasuh C.
Blommestein, Hedwig M.
Riemsma, Rob
Armstrong, Nigel
Clay, Fiona J.
Ross, Janine
Worthy, Gill
Severens, Johan
Kleijnen, Jos
Al, Maiwenn J.
[J]. PHARMACOECONOMICS, 2017, 35 (12) : 1211 - 1221
[8] Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Nasuh C. Büyükkaramikli
Hedwig M. Blommestein
Rob Riemsma
Nigel Armstrong
Fiona. J. Clay
Janine Ross
Gill Worthy
Johan Severens
Jos Kleijnen
Maiwenn J. Al
[J]. PharmacoEconomics, 2017, 35 : 1211 - 1221
[9] Health state utility values associated with advanced gastric, oesophageal, or gastro-oesophageal junction adenocarcinoma: a systematic review
Carter, Gebra Cuyun
King, Denise T.
Hess, Lisa M.
Mitchell, Stephen A.
Taipale, Kaisa-Leena
Kiiskinen, Urpo
Rajan, Narayan
Novick, Diego
Liepa, Astra M.
[J]. JOURNAL OF MEDICAL ECONOMICS, 2015, 18 (11) : 954 - 966
[10] A SYSTEMATIC REVIEW OF HEALTH-STATE UTILITY VALUES IN ADVANCED GASTRIC, OESOPHAGEAL, OR GASTRO-OESOPHAGEAL JUNCTION ADENOCARCINOMA
Carter, Cuyun G.
King, D. T.
Mitchell, S. A.
Hess, L. M.
Taipale, K. L.
Kiiskinen, U.
Rajan, N.
Novick, D.
Liepa, A. M.
[J]. VALUE IN HEALTH, 2014, 17 (03) : A92 - A92

← 1 2 3 4 5 →